Medical Care Technologies Inc. (OTC Pink:MDCE) Sees Significant Surge in Investor Activity as Share Structure Stabilizes and New Tech Partnership Forms

Rhea-AI Summary

Medical Care Technologies (OTC Pink: MDCE) announced increased trading activity and shareholder engagement as of December 9, 2025, citing a stabilization of its share structure after the close of dilution tied to a prior Regulation A offering.

The company highlighted accelerating development of AI health tools, including a Google-backed AI dermatology and wound-monitoring platform for melanoma detection and chronic wound management, plus expanded technical advisory and integration efforts as catalysts for renewed investor interest.

Management said these advances support a path toward consumer testing, commercialization, and long-term revenue execution, and that further updates will follow as execution milestones are reached.

Positive

• Reg A dilution concluded, improving share-structure stability
• Google-backed AI dermatology and wound-monitoring platform announced
• Rising trading volume and share price indicating renewed investor interest
• Accelerated product development timelines toward consumer testing

Negative

• None.

News Market Reaction

-14.29%

1 alert

-14.29% News Effect

On the day this news was published, MDCE declined 14.29%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Share price: $0.0004 24h price change: -16.67% Today’s volume: 62,888,866 shares +5 more

8 metrics

Share price $0.0004 Pre-news current price

24h price change -16.67% Move into this article

Today’s volume 62,888,866 shares Compared with 20-day avg 49,205,049 shares

20-day avg volume 49,205,049 shares Liquidity baseline before news

52-week high $0.0024 Pre-news reference level

52-week low $0.0001 Pre-news reference level

Melanoma early-detection survival up to 99% Cited benefit of earlier melanoma detection

Chronic wound prevalence 50 million+ people Global chronic wound burden cited in prior AI release

Market Reality Check

Price: $0.0003 Vol: Volume 62,888,866 vs 20-d...

normal vol

$0.0003 Last Close

Volume Volume 62,888,866 vs 20-day avg 49,205,049 (relative 1.28x) ahead of this release. normal

Technical Price at $0.0004, listed as trading above 200-day MA of $0.0000 in the data.

Peers on Argus

Peers showed mixed moves: YUKA -5.45%, BBTT +1.52%, others flat. MDCE’s -16.67% ...

Peers showed mixed moves: YUKA -5.45%, BBTT +1.52%, others flat. MDCE’s -16.67% 24h change appears more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	AI partnership update	Positive	-14.3%	Highlights rising activity, stabilized share structure, and new AI tech focus.
Dec 08	AI product update	Positive	+0.0%	Details Google-backed dermatology model in wound and skin monitoring app.
Dec 05	Reg A closure	Positive	+40.0%	Announces formal end of Reg A dilution and focus on 2026 growth.
Dec 04	AI strategy shift	Positive	+0.0%	Outlines AI health and wellness app strategy using existing subsidiaries.
Dec 03	Lean AI model	Positive	+0.0%	Describes lean outsourced AI model and pending patent application.

Pattern Detected

Recent MDCE news has mostly been framed as positive, but price reactions have often been flat or negative, with only the Reg A closing drawing a clear positive move.

Recent Company History

Over the last week, MDCE issued multiple announcements highlighting a lean AI-driven strategy, subsidiary revenue support, and the formal close of its Regulation A Tier 1 offering on December 6, 2025. Subsequent releases emphasized integration of Google-backed dermatology AI and today’s partnership-focused update on AI dermatology and wound monitoring. Despite this string of growth-oriented messages, only the Reg A closure saw a clearly positive +40% reaction, while today’s partnership-tagged news coincided with a -14.29% move.

Market Pulse Summary

The stock dropped -14.3% in the session following this news. A negative reaction despite growth-orie...

Analysis

The stock dropped -14.3% in the session following this news. A negative reaction despite growth-oriented messaging fits the recent pattern where AI and strategy updates have not consistently translated into sustained upside. The current price of $0.0004, down 16.67% over 24 hours, also sat well below the $0.0024 52-week high. Past partnership-tagged news on Jul 28, 2025 coincided with a -33.33% move, so weakness around partnership narratives has precedent and could reflect skepticism about execution and prior dilution.

Key Terms

regulation a, melanoma, dermatology, chronic wounds

4 terms

regulation a regulatory

"leaves behind dilution tied to its previous Regulation A offering."

Regulation A is a U.S. securities rule that lets smaller or growing companies offer shares to the public with simpler paperwork and lower costs than a full stock market listing, acting as a middle ground between private fundraising and a traditional public offering. For investors it matters because it opens access to early-stage opportunities that would otherwise be private, but these offerings can carry higher risk and different disclosure standards than large, fully listed companies.

melanoma medical

"platform, designed to support early detection of melanoma and the remote"

Melanoma is a serious form of skin cancer that starts in the cells that give skin its color and can grow quickly, often spreading to other parts of the body if not caught early. Investors watch melanoma because its incidence, new treatments, clinical trial results, and regulatory approvals can meaningfully affect drug and device makers’ sales, healthcare costs, and insurer liabilities—similar to how a major product success or failure moves value in other industries.

dermatology medical

"artificial intelligence tools-particularly its Google-backed AI dermatology and wound-monitoring platform"

Dermatology is the medical specialty focused on the diagnosis and treatment of conditions affecting the skin, hair and nails, including rashes, infections, chronic diseases and cosmetic concerns. It matters to investors because breakthroughs, approved treatments, new devices or shifts in care demand can change revenue prospects for drugmakers, device makers and clinics—think of it like weather changes that reshape a farmer’s crop yields, where regulatory approvals and patient demand drive financial outcomes.

chronic wounds medical

"remote management of chronic wounds for millions of patients globally."

Chronic wounds are injuries to the skin or underlying tissue that do not follow the normal healing timetable and remain open or inflamed for weeks or months, often because of poor blood flow, infection, or other health problems. For investors, chronic wounds represent a steady medical need with large treatment, device, and care markets—like a persistent household leak that requires ongoing repairs—so new therapies, regulatory approvals, or cost changes can affect company revenue and healthcare spending.

AI-generated analysis. Not financial advice.

MESA, ARIZONA / ACCESS Newswire / December 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is pleased to announce a marked rise in trading activity and shareholder engagement as the Company transitions into a new phase of technology-driven growth and leaves behind dilution tied to its previous Regulation A offering.

Over recent trading sessions, MDCE has experienced substantial increases in both share price and trading volume, signaling renewed attention from retail and strategic investors tracking the Company's emerging footprint in the high-growth AI health-technology sector.

This shift aligns with the Company's accelerated development of artificial intelligence tools-particularly its Google-backed AI dermatology and wound-monitoring platform, designed to support early detection of melanoma and the remote management of chronic wounds for millions of patients globally.

"This renewed momentum reflects a clear vote of confidence in our direction and in the future we're building," stated CEO Marshall Perkins III.
"With dilution from our prior Reg A ending and new AI partnerships propelling us forward, MDCE is entering an exciting era of innovation and value creation."

Growth Drivers Supporting Investor Excitement

MDCE attributes this increasing market interest to several key catalysts:

• Conclusion of Reg A dilution - creating a more stable and attractive share structure
• New AI-health technology integrations - including melanoma-detection capabilities
• Accelerated product development timelines
• Expansion of technical advisory and integration collaboration efforts
• Growing visibility across the investor community

Together, these advancements establish a strong foundation as MDCE scales toward consumer testing, commercialization, and long-term revenue execution.

Positioned to Capture Major Market Opportunities

With dermatology and wound-care markets representing a combined multi-billion-dollar global opportunity, MDCE believes its mobile, consumer-focused AI strategy is ideally positioned to disrupt conventional preventive-care models.

"We are moving fast, building smart, and driving toward a future where AI health tools are widely accessible," added Perkins.
"Our shareholders are recognizing the scale of what we're creating, and this is only the beginning."

MDCE will continue to provide updates as execution milestones are reached.

About Medical Care Technologies Inc. (OTC Pink:MDCE)

Medical Care Technologies Inc. is an emerging leader in AI-driven preventive and remote health solutions. The Company develops intelligent imaging tools that enable users and care providers to identify and manage critical health conditions earlier and more effectively-from any smartphone, anywhere in the world.
Learn more at: www.medicalcaretechnologies.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding anticipated market performance, technology development, milestones, financial expectations, regulatory strategy, and shareholder value creation. Forward-looking statements involve risks and uncertainties. Actual results may differ materially. MDCE undertakes no obligation to update or revise forward-looking statements to reflect future developments or events.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)

View the original press release on ACCESS Newswire

FAQ

What did Medical Care Technologies (MDCE) announce on December 9, 2025 about share structure?

The company said dilution from its prior Regulation A offering has ended, creating a more stable share structure.

What AI product developments did MDCE describe in the December 9, 2025 announcement?

MDCE described a Google-backed AI dermatology and wound-monitoring platform for melanoma detection and remote chronic-wound management.

How is investor interest changing for MDCE according to the December 9, 2025 release?

The company reported substantial increases in trading volume and share price, signaling renewed retail and strategic investor attention.

What next steps did MDCE outline for commercialization after the December 9, 2025 update?

MDCE said it is scaling toward consumer testing and commercialization and will provide updates as execution milestones are reached.

Does the MDCE announcement on December 9, 2025 mention revenue or earnings figures?

No; the announcement highlights development progress and market activity but does not disclose revenue or earnings figures.